GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zealand Pharma A/S ZEAL.CO · DKK

Health Care · Nasdaq Copenhagen · 🇩🇰 Denmark

Compare

245.00

+5.20%

Close of 9 Nov 2026, in DKK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in DKK, from our data supplier.

FY2025

Revenue

DKK 9.21bn

FY2016FY2025

Net income

DKK 6.46bn

FY2016FY2025

Free cash flow

DKK 6.50bn

FY2016FY2025

Shareholders' equity

DKK 14.83bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueDKK 9.21bnDKK 62.7mDKK 342.8mDKK 104.0mDKK 292.6mDKK 353.3mDKK 41.3mDKK 38.0mDKK 139.8mDKK 234.8m
Research and developmentDKK 1.58bnDKK 919.9mDKK 684.9mDKK 614.0mDKK 588.5mDKK 604.1mDKK 561.4mDKK 438.2mDKK 324.7mDKK 268.2m
Operating incomeDKK 7.16bn−DKK 1.27bn−DKK 572.2m−DKK 915.6m−DKK 1.05bn−DKK 832.8m−DKK 587.9mDKK 652.4m−DKK 255.1m−DKK 118.6m
Net incomeDKK 6.46bn−DKK 1.08bn−DKK 703.7m−DKK 965.6m−DKK 1.02bn−DKK 846.7m−DKK 571.5mDKK 581.3m−DKK 272.3m−DKK 153.9m
Diluted earnings per share91.42-15.27-12.05-19.39-23.33-20.09-15.8518.85-8.85-6.02

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsDKK 16.46bnDKK 9.51bnDKK 1.98bnDKK 1.54bnDKK 2.07bnDKK 1.92bnDKK 1.60bnDKK 1.23bnDKK 737.2mDKK 694.6m
Cash and short-term investmentsDKK 15.11bnDKK 8.23bnDKK 1.63bnDKK 1.18bnDKK 1.43bnDKK 1.16bnDKK 1.38bnDKK 1.16bnDKK 663.8mDKK 323.3m
Total liabilitiesDKK 1.63bnDKK 888.9mDKK 387.2mDKK 723.9mDKK 1.14bnDKK 747.5mDKK 356.8mDKK 113.5mDKK 208.8mDKK 416.4m
DebtDKK 325.6mDKK 391.8mDKK 119.2mDKK 524.1mDKK 787.4mDKK 130.1mDKK 85.8m—DKK 135.7mDKK 332.2m
Shareholders' equityDKK 14.83bnDKK 8.62bnDKK 1.59bnDKK 815.9mDKK 927.8mDKK 1.18bnDKK 1.24bnDKK 1.12bnDKK 528.5mDKK 278.2m
Shares outstanding71m71m58m50m44m42m36m31m31m26m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsDKK 6.53bn−DKK 930.8m−DKK 425.7m−DKK 942.2m−DKK 1.21bn−DKK 688.7m−DKK 409.5m−DKK 460.4m−DKK 278.7mDKK 40.9m
Capital spending−DKK 33.4m−DKK 13.1m−DKK 23.7m−DKK 11.7m−DKK 22.1m−DKK 25.0m−DKK 23.5m−DKK 4.0m−DKK 7.2m−DKK 2.6m
Free cash flowDKK 6.50bn−DKK 944.0m−DKK 449.4m−DKK 953.9m−DKK 1.23bn−DKK 713.8m−DKK 433.0m−DKK 464.4m−DKK 286.0mDKK 38.3m
Dividends paid————−DKK 647.9m—————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueDKK 4.49bnDKK 34.0mDKK 68.9mDKK 49.6mDKK 9.09bnDKK 8.1mDKK 9.1mDKK 4.4m
Operating incomeDKK 3.86bn−DKK 539.0m−DKK 510.6m−DKK 461.3mDKK 8.34bn−DKK 407.0m−DKK 399.3m−DKK 349.4m
Net incomeDKK 3.92bn−DKK 394.0m−DKK 379.1m−DKK 404.2mDKK 7.57bn−DKK 335.3m−DKK 291.0m−DKK 266.4m
Diluted earnings per share55.34-5.57-5.37-5.73107.27-4.75-4.12-3.77
Cash from operationsDKK 406.0m−DKK 672.0m−DKK 1.04bn−DKK 443.0mDKK 8.52bn−DKK 500.0m−DKK 180.0m−DKK 295.0m
Capital spending−DKK 13.0m−DKK 11.0m−DKK 16.0m−DKK 3.0m−DKK 6.0m−DKK 8.0m−DKK 2.0m—
Free cash flowDKK 393.0m−DKK 683.0m−DKK 1.06bn−DKK 446.0mDKK 8.51bn−DKK 508.0m−DKK 182.0m—
Total assetsDKK 19.76bnDKK 15.30bnDKK 16.46bnDKK 16.80bnDKK 17.18bnDKK 9.12bnDKK 9.51bnDKK 9.63bn
Cash and short-term investmentsDKK 14.46bnDKK 14.47bnDKK 15.11bnDKK 16.17bnDKK 16.58bnDKK 8.54bnDKK 8.23bnDKK 8.47bn
DebtDKK 29.0mDKK 336.0mDKK 348.2mDKK 321.0mDKK 311.5mDKK 322.7mDKK 317.4mDKK 312.9m
Shareholders' equityDKK 18.00bnDKK 14.47bnDKK 14.83bnDKK 15.16bnDKK 15.61bnDKK 8.31bnDKK 8.62bnDKK 8.88bn

Financial ratios

Data as of 22 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin77.7%-2029.3%-166.9%-880.5%-359.0%-235.7%
Net margin70.0%-1720.9%-205.3%-928.6%-348.0%-239.7%
Return on equity43.5%-12.5%-44.2%-118.3%-109.7%-71.9%
Return on assets39.2%-11.3%-35.5%-62.7%-49.2%-44.0%
Free cash flow yield34.0%-4.8%-2.5%-6.8%-10.0%-5.8%
Revenue growth14598.9%-81.7%229.6%-64.5%-17.2%754.8%
Earnings growth-698.3%53.3%-27.1%-5.2%20.2%48.1%
Current ratio23.57x21.14x6.25x6.73x5.15x2.16x
Debt to equity0.02x0.03x0.01x0.41x0.71x0.01x
Equity ratio90.1%90.6%80.4%53.0%44.9%61.2%
Interest coverage189.81x-31.11x-19.75x-16.22x-256.71x-107.82x
R&D as a share of sales17.2%1467.3%199.8%590.5%201.1%171.0%
Buybacks as a share of market value0.1%-21.0%-17.2%-14.2%-3.5%-16.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue345.8%92.0%47.6%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin63.4%45.2%24.2%19.3%
Net margin57.9%38.1%17.8%11.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings3.3-29.8-19.7-6.6-4.0-7.0-9.42.8-6.1-11.3
Price to sales2.3—40.461.413.816.7130.642.611.97.4

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.